Europe Cancer Immunotherapy Market By Technology (Monoclonal Antibodies, Cytokines & Immunomodulators), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer), End User (Hospitals, Clinics)

The Europe Cancer Immunotherapy Market would witness market growth of 13.5 % CAGR during the forecast period (2018 – 2024).  Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Click Here For Free Insights:

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Scope of the Study

Market Segmentation:

By Technology

• Monoclonal Antibodies,
• Cytokines & Immunomodulators
• Other technology

By Application

•  Lung cancer
•  Breast cancer
• Colorectal
•  Prostate cancer
• Head & Neck cancer
• Other application.

By End User

• Hospitals
• Clinics
• Other End User

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• AstraZeneca
• Amgen Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Bayer Ag
• Immunomedics Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd

Chapter 1.    Market Scope & Methodology
1.1    Market Definition
1.2    Objectives
1.3    Market Scope
1.4    Segmentation
1.4.1    Europe Cancer Immunotherapy Market, by Technology
1.4.2    Europe Cancer Immunotherapy Market, by Application
1.4.3    Europe Cancer Immunotherapy Market, by End User
1.4.4    Europe Cancer Immunotherapy Market, by Countries
1.5    Methodology for the research
Chapter 2.    Market Overview
2.1    Introduction
2.2    Key Factors Impacting the Market
2.2.1    Market Drivers
2.2.2    Market Restraints
Chapter 3.    Europe Cancer Immunotherapy Market by Technology
3.1.1    Europe Monoclonal Antibodies Cancer Immunotherapy Market by Country
3.1.2    Europe Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
3.1.3    Europe Other Technology Cancer Immunotherapy Market by Country
Chapter 4.    Europe Cancer Immunotherapy Market by Application
4.1.1    Europe Cancer Immunotherapy Lung Cancer Market by Country
4.1.2    Europe Cancer Immunotherapy Breast Cancer Market by Country
4.1.3    Europe Cancer Immunotherapy Colorectal Cancer Market by Country
4.1.4    Europe Cancer Immunotherapy Melanoma Market by Country
4.1.5    Europe Cancer Immunotherapy Prostate Cancer Market by Country
4.1.6    Europe Cancer Immunotherapy Head & Neck Cancer Market by Country
4.1.7    Europe Other Application Cancer Immunotherapy Market by Country
Chapter 5.    Europe Cancer Immunotherapy Market by End User
5.1.1    Europe Hospitals Cancer Immunotherapy Market by Country
5.1.2    Europe Clinics Cancer Immunotherapy Market by Country
5.1.3    Europe Other End User Cancer Immunotherapy Market by Country
Chapter 6.    Europe Cancer Immunotherapy Market by Country
6.1    Germany Cancer Immunotherapy Market
6.1.1    Germany Cancer Immunotherapy Market by Technology
6.1.2    Germany Cancer Immunotherapy Market by Application
6.1.3    Germany Cancer Immunotherapy Market by End User
6.2    UK Cancer Immunotherapy Market
6.2.1    UK Cancer Immunotherapy Market by Technology
6.2.2    UK Cancer Immunotherapy Market by Application
6.2.3    UK Cancer Immunotherapy Market by End User
6.3    France Cancer Immunotherapy Market
6.3.1    France Cancer Immunotherapy Market by Technology
6.3.2    France Cancer Immunotherapy Market by Application
6.3.3    France Cancer Immunotherapy Market by End User
6.4    Russia Cancer Immunotherapy Market
6.4.1    Russia Cancer Immunotherapy Market by Technology
6.4.2    Russia Cancer Immunotherapy Market by Application
6.4.3    Russia Cancer Immunotherapy Market by End User
6.5    Spain Cancer Immunotherapy Market
6.5.1    Spain Cancer Immunotherapy Market by Technology
6.5.2    Spain Cancer Immunotherapy Market by Application
6.5.3    Spain Cancer Immunotherapy Market by End User
6.6    Italy Cancer Immunotherapy Market
6.6.1    Italy Cancer Immunotherapy Market by Technology
6.6.2    Italy Cancer Immunotherapy Market by Application
6.6.3    Italy Cancer Immunotherapy Market by End User
6.7    Rest of Europe Cancer Immunotherapy Market
6.7.1    Rest of Europe Cancer Immunotherapy Market by Technology
6.7.2    Rest of Europe Cancer Immunotherapy Market by Application
6.7.3    Rest of Europe Cancer Immunotherapy Market by End User
Chapter 7.    Company Profiles
7.1    Amgen Inc.
7.1.1    Company Overview
7.1.2    Financial Analysis
7.1.3    Segmental & Regional Analysis
7.1.4    Research and Development Expense
7.2    Merck & Company, Inc.
7.2.1    Company Overview
7.2.2    Financial Analysis
7.2.3    Regional and Segmental Analysis
7.2.4    Research & Development
7.3    Pfizer Inc.
7.3.1    Company Overview
7.3.2    Financial Analysis
7.3.3    Segmental &Regional Analysis
7.3.4    Revenue analysis by Region
7.3.5    Research and Development
7.4    Immunomedics Inc.
7.4.1    Company Overview
7.4.2    Financial Analysis
7.4.3    Revenue Analysis by Region
7.4.4    Research and Development
7.5    Astrazeneca Plc.
7.5.1    Company Overview
7.5.2    Financial Analysis
7.5.3    Segmental analysis
7.5.4    Research & Development
7.6    F. Hoffmann-La Roche Ltd.
7.6.1    Company Overview
7.6.2    Financial Analysis
7.6.3    Revenue & Segment analysis
7.6.4    Research and Development
7.7    Eli Lilly and Company
7.7.1    Company Overview
7.7.2    Financial Analysis
7.7.3    Segmental and Regional Analysis
7.7.4    Research & Development Expense
7.8    Novartis AG
7.8.1    Company Overview
7.8.2    Financial Analysis
7.8.3    Segmental and Regional Analysis
7.8.4    Research & Development Expense
7.9    Bristol-Myers Squibb Company
7.9.1    Company Overview
7.1    Bayer AG
7.10.1    Company Overview
7.10.2    Financial Analysis
7.10.3    Segmental and Regional Analysis
7.10.4    Research & Development Expense

TABLE 1    EUROPE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 2    EUROPE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 3    EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 4    EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 5    EUROPE MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 6    EUROPE MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 7    EUROPE CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 8    EUROPE CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 9    EUROPE OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 10    EUROPE OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 11    EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 12    EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 13    EUROPE CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 14    EUROPE CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 15    EUROPE CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 16    EUROPE CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 17    EUROPE CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 18    EUROPE CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 19    EUROPE CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 20    EUROPE CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 21    EUROPE CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 22    EUROPE CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 23    EUROPE CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 24    EUROPE CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 25    EUROPE OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 26    EUROPE OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 27    EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 28    EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 29    EUROPE HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 30    EUROPE HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 31    EUROPE CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 32    EUROPE CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 33    EUROPE OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 34    EUROPE OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 35    EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 36    EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 37    GERMANY CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 38    GERMANY CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 39    GERMANY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 40    GERMANY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 41    GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 42    GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 43    GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 44    GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 45    UK CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 46    UK CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 47    UK CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 48    UK CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 49    UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 50    UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 51    UK CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 52    UK CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 53    FRANCE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 54    FRANCE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 55    FRANCE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 56    FRANCE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 57    FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 58    FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 59    FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 60    FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 61    RUSSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 62    RUSSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 63    RUSSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 64    RUSSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 65    RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 66    RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 67    RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 68    RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 69    SPAIN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 70    SPAIN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 71    SPAIN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 72    SPAIN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 73    SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 74    SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 75    SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 76    SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 77    ITALY CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 78    ITALY CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 79    ITALY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 80    ITALY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 81    ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 82    ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 83    ITALY CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 84    ITALY CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 85    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 86    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 87    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 88    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 89    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 90    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 91    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 92    REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 93    KEY INFORMATION-AMGEN INC.
TABLE 94    KEY INFORMATION-MERCK & COMPANY INC.
TABLE 95    KEY INFORMATION- PFIZER INC.
TABLE 96    KEY INFORMATION- IMMUNOMEDICS INC.
TABLE 97    KEY INFORMATION- ASTRAZENECA PLC.
TABLE 98    KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
TABLE 99    KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 100    KEY INFORMATION – NOVARTIS AG
TABLE 101    KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
TABLE 102    KEY INFORMATION – BAYER AG